A novel compound, SGL5213, has been identified as a selective iSGLT1 inhibitor, and has demonstrated insulin-sensitizing, anti-inflammatory, and antifibrotic activity in a murine model of NAFLD [162]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.